Pluristem Therapeutics Inc (PSTI)

[El Mago]

Stem Cell Innovations Cites Two Recent Government Documents Supporting the Use of Cell-Based Assays for Toxicity Testing
Stem Cell Innovations (SCLL.OB) (SCI) noted that two recent government panels, one in the US and one in the UK, advocate the use of cell-based assays for toxicity testing. The Company’s human liver-based ACTIVTox® and stem cell-based PluriCell™ systems are specifically designed for this purpose.

The National Research Council, part of the US National Academy of Sciences, published a report entitled “Toxicity Testing in the 21st Century: a Vision and a Strategy” promoting the use of cell-based models for toxicity testing. Another report entitled “Stem Cells in Predictive Toxicology”, published by the Dept of Health and the Dept of Trade and Industry in the United Kingdom, specifically encouraged the establishment of stem cell-based assays to speed and standardize toxicity testing.

“These two reports, one in the US and one in the UK, affirm SCI’s strategy of using human cell-based assays, rather than animal models, to assess toxicity in new drugs and chemicals,’ said James H. Kelly, PhD, CEO of Stem Cell Innovations. “The UK report, in particular, cites liver, heart and neural models as the top priority, corresponding exactly to those established at SCI.” The Company’s ACTIVTox is a high throughput, human liver-based system used to identify and eliminate toxic liabilities in new drugs. It is currently available as either a kit or a service. Customers can run the assays in house or ship compounds to SCI for evaluation. The Company’s PluriCell stem cell-based system is being used to develop both neural and cardiac models.

The NRC report can be found at http://www.nap.edu/catalog.php?record_id=11970. The UK Dept of Health report can be found at http://www.sc4sm.org/downloads/SC4PT-REPORT.pdf.

About Stem Cell Innovations, Inc.

SCI is a cell biology company with an office in Scotch Plains, N.J., and facilities in Houston, TX. The Company’s ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company’s currently marketed ACTIVTox toxicology offerings.

Additional information is available at www.stemcellinnovations.com.

ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.

Forward Looking Statement